reported side effects of eptifibatide
major hemorrhage
minor hemorrhage
comprehensive list of adverse effects
approval by the fda
efficacy
safety of eptifibatide
patients
average age of these patients
years
range
percent
percent
common side effect
bleeding
discontinuation of eptifibatide
adverse events
bleeding
single event
study population
overall incidence of intracranial hemorrhage
stroke in large clinical trials
patients
depending on dose
incidences of thrombocytopenia
need for platelet transfusions
patients
eptifibatide
placebo
suggesting
stronger relationship between these problems
use of heparin
use of the study drug
bleeding times
activated clotting times
treated patients
placebo
cases
receiving
receiving less heparin
incidence of thrombocytopenia
cells/mcl
eptifibatide
severe thrombocytopenia
cells/mcl
patients
platelet transfusions
patients
results
study
protect-timi
trial
high-risk non st segment elevation
acute coronary syndrome patients
undergoing percutaneous coronary intervention
pci
eptifibatide
age
bleeding events
patients
reduced crcl
ml/min
full-dose eptifibatide infusion
greater incidence
bleeding events
bleeding events
patients
reduced crcl
reduced dose infusion
addition
majority
bleeding events
hours after initiation of the eptifibatide infusion
risk factors
bleeding events in patients
glycoprotein
gp
iib/iiia inhibitors
undergoing percutaneous coronary intervention
advanced age
renal dysfunction
female gender
peripheral vascular disease
lower body weight
duration of gp iib/iiia inhibitor infusion
baseline platelet count
lower baseline hemoglobin
diabetes
elevated peak activated clotting time
according
study
crusade trial
involving patients with non st segment elevation
acute coronary syndrome
gpiib/iiia inhibitor
women
greater risk of bleeding than men
excessive dosing
hematologic side effects
incidences of major
intracranial hemorrhage
hemoglobin of mg/dl
minor bleeding
spontaneous gross hematuria
hematemesis
hemoglobin of less than mg/dl
pursuit study
impact
study
incidences of the transfusion requirements in these
studies
overall incidence of major bleeding
incidence of coronary artery bypass graft surgery
arterial puncture sites
common sites of bleeding
occurring
patients
oropharyngeal
incidences of upper
lower gi bleeding
retroperitoneal
pursuit study
risk of major bleeding
body weight
patients
kg
highest correlation
bleeding
reason
therapy
patients
fatal bleeding
thrombocytopenia
pulmonary hemorrhage
combination with aspirin
heparin
postmarketing experience
hypersensitivity reactions
anaphylaxis
patients
cardiovascular
side effects
hypotension
placebo patients
other cardiovascular side effects
underlying disease
side effects among patients with unstable angina
nervous system
side effects
non hemorrhagic stroke
placebo patients in controlled trials
musculoskeletal discomfort
pain
more patients
eptifibatide
placebo patients in the impact ii trial
local intravenous site reactions
more treated patients
placebo patients in controlled trials
arterial access sites
common sites of bleeding
immunologic side effects
postmarketing reports of igg antibodies
immune-mediated thrombocytopenia
stomach pain
swelling
pain
backaches
bleeding from the bladder
bleeding gums
blood in the urine
tarry stools
blurred vision
confusion
constipation
coughing up blood
difficulty with breathing
swallowing
dizziness
dizziness
faintness
lightheadedness
getting
lying
sitting position
headache
headache
increased menstrual flow
vaginal bleeding
nausea and vomiting
nosebleeds
paralysis
prolonged bleeding from cuts
tarry stools
dark brown urine
severe stomach pain
shortness of breath
sweating
unusual tiredness
weakness
vomiting of blood
material
coffee grounds
weakness
pinpoint
red spots on the skin
cough
difficulty with swallowing
fast heartbeat
hives
itching
puffiness
swelling of the eyelids
eyes
face
lips
tongue
skin rash
tightness in the chest
wheezing
difficulty with speaking
double vision
inability
arms
legs
facial muscles
inability to speak
slow speech